Dan Costin

688 total citations
21 papers, 559 citations indexed

About

Dan Costin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dan Costin has authored 21 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Dan Costin's work include Peptidase Inhibition and Analysis (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Dan Costin is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Dan Costin collaborates with scholars based in United States, United Kingdom and Spain. Dan Costin's co-authors include M Potmĕsil, R Silber, Soumaya El Rouby, Alexander S. Thomas, Viola W. Zhu, Petros Nikolinakos, Vincent A. Miller, Jeffrey S. Ross, Sai‐Hong Ignatius Ou and Wen-Son Hsieh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dan Costin

21 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan Costin United States 7 297 276 202 185 156 21 559
Alexander S. Thomas United States 10 317 1.1× 347 1.3× 268 1.3× 189 1.0× 79 0.5× 21 681
Monica Ceccon Italy 13 295 1.0× 97 0.4× 311 1.5× 133 0.7× 258 1.7× 20 650
Milena Pantić Germany 12 106 0.4× 224 0.8× 364 1.8× 116 0.6× 44 0.3× 34 713
Shivakumar Subramaniyam United States 10 177 0.6× 74 0.3× 350 1.7× 147 0.8× 47 0.3× 21 624
TW Mak Canada 9 198 0.7× 200 0.7× 144 0.7× 290 1.6× 47 0.3× 13 671
Brian J. Capaldo United States 11 89 0.3× 88 0.3× 155 0.8× 70 0.4× 104 0.7× 26 439
Josephine L. Klitgaard United States 7 133 0.4× 171 0.6× 178 0.9× 97 0.5× 35 0.2× 11 426
S Potoczek Poland 11 144 0.5× 341 1.2× 110 0.5× 279 1.5× 49 0.3× 41 613
Ángel Ramírez Páyer Spain 12 263 0.9× 172 0.6× 162 0.8× 116 0.6× 25 0.2× 33 609
Evgenii A. Osmanov Russia 6 316 1.1× 207 0.8× 110 0.5× 352 1.9× 42 0.3× 22 493

Countries citing papers authored by Dan Costin

Since Specialization
Citations

This map shows the geographic impact of Dan Costin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Costin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Costin more than expected).

Fields of papers citing papers by Dan Costin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Costin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Costin. The network helps show where Dan Costin may publish in the future.

Co-authorship network of co-authors of Dan Costin

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Costin. A scholar is included among the top collaborators of Dan Costin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Costin. Dan Costin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
6.
7.
Shore, Neal D., Begoña Mellado, Satish Shah, et al.. (2021). A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 85–85. 3 indexed citations
8.
Aggarwal, Rahul, Dan Costin, Jingsong Zhang, et al.. (2021). BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). 124–124. 4 indexed citations
9.
Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 140–140. 1 indexed citations
10.
Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). e17581–e17581. 6 indexed citations
11.
Noyer, Charles M., Dan Costin, Sasan Roayaie, et al.. (2020). Early detection for pancreatic cancer in individuals at elevated-risk, using endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) of the abdomen: Feasibility and preliminary outcomes.. Journal of Clinical Oncology. 38(15_suppl). e16798–e16798. 2 indexed citations
12.
Aggarwal, Rahul, Dan Costin, Jingsong Zhang, et al.. (2020). 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC). SHILAP Revista de lepidopterología. A208–A209. 3 indexed citations
13.
Schrock, Alexa B., Viola W. Zhu, Wen-Son Hsieh, et al.. (2018). Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. 13(9). 1312–1323. 107 indexed citations
14.
Ou, Sai‐Hong Ignatius, Samuel J. Klempner, Ben Creelan, et al.. (2017). MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(11). S1848–S1848. 2 indexed citations
15.
Kolev, Valentin, Dan Costin, Howard H. Mizrachi, et al.. (2012). Primary pulmonary carcinoid tumor with metastasis to endometrial polyp. International Journal of Surgery Case Reports. 4(1). 91–93. 3 indexed citations
16.
Costin, Dan & M Potmĕsil. (1994). Preclinical and Clinical Development of Camptothecins. Advances in pharmacology. 29B. 51–72. 17 indexed citations
17.
18.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander S. Thomas Breakdown of academic impact, for papers by Monica Ceccon Breakdown of academic impact, for papers by Milena Pantić Breakdown of academic impact, for papers by Shivakumar Subramaniyam Breakdown of academic impact, for papers by TW Mak Breakdown of academic impact, for papers by Brian J. Capaldo Breakdown of academic impact, for papers by Josephine L. Klitgaard Breakdown of academic impact, for papers by S Potoczek Breakdown of academic impact, for papers by Ángel Ramírez Páyer Breakdown of academic impact, for papers by Evgenii A. Osmanov
Rankless by CCL
2026